Antinuclear factor in dermatology;Fator antinúcleo na dermatologia

Anais Brasileiros de Dermatologia

Volumn 80, Issue 4, 2005, Pages 387-394

  Duarte, Artur Antônio ^a,b  

^a UNIVERSITY OF SANTO AMARO   (Brazil)

^b NONE   (Brazil)

Author keywords

Antinuclear antibodies; Autoimmunity; Collagen diseases; Fluorescent antibody technique

Indexed keywords

ANTINUCLEAR ANTIBODY;

ASSAY; AUTOIMMUNITY; CLINICAL PRACTICE; COLLAGEN DISEASE; GENERAL PRACTITIONER; HISTOPATHOLOGY; HUMAN; PATHOPHYSIOLOGY; REVIEW;

EID: 26244463942     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962005000400010     Document Type: Review

References (54)

1. Dellavance A, Gabriel Jr A, Cintra FU, Ximenes AC, Nuccitelli B, Taliberti BH, et al. II Consenso Brasileiro de Fator Antinúcleo em Células HEp-2. Rev Bras Reumatol. 2003;43:129-40.
2. Duarte AA. Lúpus Eritematoso. In: Duarte AA, editor. Colagenoses e a Dermatologia. São Paulo: 2004. p. 12-38.
3. Holman HR, Kunkel HG. Affinity between the lupus erythematosus serum factor and cell nuclei and nucleo protein. Science. 1957;126:162-71.
4. Neugebauer KM, Merril JT, Werner MH. SR protein are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthritis Rheum. 2000; 43:1768-78.
5. Hargraves MM, Richmond H, Morton R. Presentation of 2 bone marrow elements: "tart" cell and "LE" cell. Proc Staff Meet Mayo Clin. 1948; 23: 25-34.
6. Hargraves MM. Production in vitro of the LE cell phenomenon: use of normal bone marrow elements and blood plasma from patients with acute disseminated lupus erythematosus. Proc Staff Mayo Clin. 1949;24:234-7.
7. Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. 5th ed. Pennsylvania: Williams & Wilkins; 1997:383-457.
8. Beck J. Antinuclear antibodies: methods of detection and significance. Mayo Clin Proc. 1960;44:600-13.
9. Friou GJ. Clinical application of lupus serum nucleoprotein reaction using fluorescent antibody technique. J Clin Invest. 1957;36:890-2.
10. Schmidt-Acevedo S, Perez-Romano B, Ruiz-Argueles A. LE cell's result from phagocytosis of apoptotic bodies induced by antinuclear antibodies. J Autoimmun. 2000;15:15-21.
11. Tan EM. The LE cell and is legacy. Clin Exp Rheum. 1998;16:652-5.
12. Beck JS. Variation in the morphological patterns of autoimmune fluorescence. Lancet. 1961;1:1203-6.
13. Casals SP, Friou GJ, Teague PO. Specific nuclear reaction pattern of antibody to DNA in lupus erythematosus sera. J Lab Clin Med. 1963;62:625-7.
14. Clark G, Reichlin M, Tomasi TB Jr. Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol. 1969;102:117-22.
15. Johnson GD, Holborow EJ. Standardisation of tests for antinuclear antibody. Ann Rheum Dis. 1980;39:529.
16. Peng SL, Craft J. Antinuclear antibodies. In: Harris ED Jr, editor. Kelley's Textbook of Rheumatology. Philadelphia: Elsevier & Saunders; 2005. p. 311-31.
17. Lahita RG, Chiorazzi N, Reeves WH. Antinuclear antibodies. In Harris ED Jr, editor. Textbook of the Autoimmune diseases. Philadelphia: Williams & Wilkins; 2000. p. 87-101.
18. Field M, Williams DG, Charles P. Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens. Ann Rheum Dis. 1988;47:820-5.
19. Mackay IR. Antinuclear (chromatin) autoantibodies in autoimmune hepatitis. J Gastroenterol Hepatol. 2001; 16:245-7.
20. Tzang BS, Chen TY, Hsu TC, Presentation of autoanti body to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection. Ann Rheum Dis. 1999;58:630-4.
21. Haserick JR, Bortz DW. Normal bone marrow inclusion phenomena induced by lupus erythematosus plasma. J Invest Dermatol. 1949; 13: 47-51.
22. Narain S, Richards HB, Satoh M, Sarmiento M, Davidson R, Shuster J, et al. Diagnostic accuracy for lupus and others systemic autoimmune diseases in the community setting. Arch Intern Med. 2004;164:2435-41.
23. Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured ker atinocytes of SLE patients after UVA/UVB irradiation. J Clin Invest. 1992;90:1067-76.
24. Molden DP, Nakamura RM, Tan EM. Standardization of the immunofluorescence test for autoantibody to nuclear antigens (ANA): use of reference sera defined antibody specificity. Am J Clin Pathol. 1984;82:57-66.
25. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the anti nuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College Pathologists. Arch Pathol Lab Med. 2000; 124: 71-81.
26. Kullick K, Provost TT, Reichilin M. Antibodies to single stranded DNA in patients with discoid lupus erythe matosus. Arthritis Rheum. 1982;25:639-46.
27. Maddison PJ, Reichlin M. Quantitation of precipitating antibodies to certain soluble nuclear antigen in systemic lupus erythematosus. Their contribution to hyperglobulinemia. Arthritis Rheum. 1977;20:819-24.
28. Mattioli M, Reichlin M. Charaterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol. 1971;107:1281-90.
29. McGhee JL, Kickingbird LM, Jarvis JN. Clinical utility of antinuclear antibody test in children. BMC Pediatr. 2004;4:13.
30. Rose NR, Mackay IR. The Autoimmune Diseases. 3 th ed. San Diego: Academic Press; 1998. p.451-98.
31. Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on immunologic Testing: Evidence-based guidelines for the use of immunologic test: antinuclear antibodies testing. Arthritis Rheum. 2002;47:546-55.
32. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erithematosus. J Immunol. 1966;96:464-71.
33. Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow-up with emphasis on the predictive value of anti nuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988;47:634-41.
34. Maddison PJ, Provost TT, Reichlin M. Serological findings in patients with "ANA-negative" systemic lupus erythematosus. Medicine. 1981;60:87-94.
35. Vaile JH, Dyke L, Kherani R, Johnston C, Higgins T, Russel AS. Is high titre ANA specific for connective tissue disease? Clin Exp Rheumatol. 2000;18:433-8.
36. Illei GG, Klippel JH. Why is the ANA result positive? Bull Rheum Dis. 1999;48:1-4.
37. Nakano M, Ohuchi Y, Hasegawa H. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheum. 2000;27:1403-10.
38. Peng SL, Hardin JA, Craft J. Antinuclear antibodies. In: Harris ED Jr, editor. Textbook of Reumatology. Philadelphia: WB Saunders; 1997. p. 250-98.
39. Deicher HRG, Holman HR, Kunkel HG. The precipitin reaction between DNA and a serum factor in systemic lupus erythematosus. J Exp Med. 1959;109:97-113.
40. Eblling FM, Hahn BH. Pathogenic subset of antibodies to DNA. Int Rev Immunol. 1989;5:79-95.
41. Hannestad K, Johannessen A. Polyclonal human antibodies to IgG (rheumatoid factors) which cross-react with cell nuclei. Scand J Immunol. 1976;5:541-7.
42. Herkel J, Mimran A, Erez N. A. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA autibodies. J Autoimmun. 2001;17:63-9.
43. Lopes-Longo FJ, Rodriguez-Mahou M, Escalona M. Heterogeneity of the anti-Ro (SSA) response in rheumatic diseases. J Rheum. 1994;21:1450-5.
44. Elkon KB, Bonfa E, Brot N. Antiribossomal antibodies in systemic lupus erythematosus. Rheum Dis Clin Nort Am. 1992;18:377-90.
45. Fritzler MJ, Salazar M. Diversity and origin of rheumatologic autoantibodies. Clin Microbiol Rev. 1991;4:256-69.
46. Townes AS, Stewart CR Jr, Osler AG. Immunologic studies of systemic lupus erythematosus. I. Quantitative estimulation of nucleoprotein-reactive gamma globulin in systemic lupus erythematosus and other diseases. Bull Johns Hopkins Hosp. 1963;112:183-96.
47. Hoogen van FH, Spronk PE, Boerbooms AM. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Br J Rheum. 1994;33:1117-20.
48. Font J, Ramos-Casals M, Cervera R. Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance. Br J Rheum. 1998;37:1287-91.
49. Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sjogren's syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am. 1992;18:337-58.
50. Rothfield NF. Autoantibodies in scleroderma. Rheum Dis Clin North Am. 1992;18:483-98.
51. Weiner ES, Hidelbrandt S, Senecal JL. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum. 1991;34:68-77.
52. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998;158:595-600.
53. Vasquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum. 1996;39:292-6.
54. Zhang Y, Le Roy G, Seelig HP. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell. 1988;95:279-89.